Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Deferred Tax (2016 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $15.2 million as the latest value for Q2 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 6.25% to $15.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was $15.2 million, a 6.25% decrease, with the full-year FY2025 number at $15.2 million, down 6.25% from a year prior.
  • Long-Term Deferred Tax was $15.2 million for Q2 2025 at PharmaCyte Biotech, down from $16.2 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $16.2 million in Q2 2024 to a low of $15.2 million in Q2 2025.